New Directions Targeting Inflammatory and Fibrotic Pathways in the Management of SSc-ILD

CME: 1.0

Patients with SSc may develop ILD early in the disease and SSc should be considered in some cases of ILD. There are new agents to treat inflammation and fibrosis in SSc-ILD.

Post a comment to this article